Get the Stockscreener App
1.14
0.88%
0.01
After Hours:
1.14
Nautilus Biotechnology Inc stock is traded at $1.14, with a volume of 88,946.
It is up +0.88% in the last 24 hours and down -28.75% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$1.13
Open:
$1.15
24h Volume:
88,946
Relative Volume:
0.70
Market Cap:
$143.81M
Revenue:
-
Net Income/Loss:
$-63.68M
P/E Ratio:
-2.1923
EPS:
-0.52
Net Cash Flow:
$-54.15M
1W Performance:
-5.00%
1M Performance:
-28.75%
6M Performance:
-58.24%
1Y Performance:
-55.12%
1-Day Range:
$1.1116
$1.23
1-Week Range:
$1.11
$1.27
52-Week Range:
$1.10
$3.09
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
1.14 | 143.81M | 0 | -63.68M | -54.15M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges - TipRanks
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology lays off 16% of workforce, plans release of commercial platform in 2026 - MSN
Nautilus: Trading Below An Albeit Lower Net Cash Figure (NASDAQ:NAUT) - Seeking Alpha
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating - Investing.com
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating By Investing.com - Investing.com South Africa
Nautilus Biotechnology Reports 2024 Financial Results - TipRanks
Seattle's Nautilus Biotechnology lays off 16% of its staff - The Business Journals
Nautilus Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Manila Times
Nautilus Cuts 16% of Workforce as Biotech Platform Launch Slips to 2026What's Next? - StockTitan
Nautilus Biotechnology Announces Board Changes for 2025 - TipRanks
Nautilus Biotechnology (NAUT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Blade Air Mobility Leads The Charge Among 3 US Penny Stocks - Simply Wall St
Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference - The Manila Times
Exclusive: Nautilus Biotech Unveils Next-Gen Protein Analysis Breakthrough at Major Healthcare Summit - StockTitan
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 68.8% in January - MarketBeat
Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Down 5.9%Time to Sell? - MarketBeat
SG Americas Securities LLC Buys 9,904 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
NAUTNautilus Biotechnology Inc Latest Stock News & Market Updates - StockTitan
Nautilus Bio Q4 Earnings Alert: Protein Analysis Pioneer Reports Feb 27 - StockTitan
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewswire
One Nautilus Biotechnology Insider Raised Their Stake In The Previous Year - Yahoo Canada Finance
Nautilus Biotech announces board member changes By Investing.com - Investing.com Australia
Nautilus Biotech announces board member changes - MSN
Nautilus Biotechnology Announces Board Member Departures - MSN
NAUTILUS BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Barclays PLC Buys 47,059 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Jeff Bezos Stock Portfolio: Top Investment Picks - CoinCodex
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in December - MarketBeat
Barclays PLC Has $1.04 Million Holdings in Northfield Bancorp, Inc. (Staten Island, NY) (NASDAQ:NFBK) - Defense World
Jane Street Group LLC Sells 25,020 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
EZCORP, Inc. (NASDAQ:EZPW) Shares Acquired by Barclays PLC - Defense World
US Penny Stocks To Watch In January 2025 - Simply Wall St
Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register
Barclays PLC Has $303,000 Stock Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
State Street Corp Lowers Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
The Manufacturers Life Insurance Company Invests $67,000 in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks - Simply Wall St
With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future - Yahoo Finance
Nautilus Biotechnology (NASDAQ:NAUT) Cut to “Sell” at The Goldman Sachs Group - Defense World
Goldman Sachs Downgrades Nautilus Biotechnology (NAUT) - MSN
Goldman Sachs cuts Nautilus Biotechnology stock to sell By Investing.com - Investing.com Canada
Goldman Sachs cuts Nautilus Biotechnology stock to sell - Investing.com
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):